CytomX plans 2026 FDA trial design discussions for varsetatug masetecan in late-line colorectal cancer
CytomX posts 2025 results with $76.2M revenue, Q4 non-GAAP EPS -$0.33 misses, cash runway into Q2 2027
- Q4 2025 non-GAAP EPS was -$0.33, down 250% YoY and missing Wall Street estimates.
- Q4 2025 revenue totaled $661,000, declining 98% year over year and coming in below revenue estimates.
- CytomX ended 2025 with $137.1 million in cash and investments on the balance sheet.
- Positive Phase 1 expansion data reported for EpCAM PROBODY ADC varsetatug masetecan in late-line colorectal cancer.
- CytomX plans 2026 FDA trial design discussions for varsetatug masetecan in late-line colorectal cancer.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.